Today, Mylab has taken an important and essential step to help India and the world fight the worst pandemic in the history of mankind. A step that will empower every Indian to fight this pandemic. We feel humbled to give India - its first Self-use Covid-19 test kit - CoviSelf. Now, every Indian can test for Covid-19 from the comfort of their homes and know the result within 15 minutes. Now we can test faster, isolate faster and get treated faster. Countless lives will be saved and we believe we will win, India will win!
Results of an interim analysis of the Phase III programme conducted by Oxford University with AZD1222, peer-reviewed and published in The Lancet on Wednesday demonstrated that the vaccine is safe and effective at preventing symptomatic COVID-19 and that it protects against severe disease and hospitalization. The interim analysis for efficacy was based on 11,636 participants accruing 131 symptomatic infections from the Phase III UK and Brazil trials conducted by Oxford University. As announced on November 23, the primary efficacy endpoint of the programme statistical plan, based on the pooling of two dosing regimens, showed that the vaccine is 70.4 per cent effective at preventing symptomatic COVID-19 occurring more than 14 days after receiving two doses of the vaccine. A secondary efficacy endpoint of prevention of severe disease demonstrated no cases of severe infections or hospitalizations in the vaccine group.
Nationalistic behavior by governments may exclude some countries from gaining access to COVID-19 vaccines and cost the global economy up to $1.2 trillion a year in GDP, according to a new study from the not-for-profit research organization RAND Europe. If countries demonstrate 'vaccine nationalism' - prioritizing their own citizens and insisting on first access to vaccines by signing deals directly with pharmaceutical companies and hoarding supplies - this could mean that, by initially immunizing only their own populations, they incur economic penalties for themselves as well as the wider global population. The study's macroeconomic analysis shows that, as long as the virus is not under control in all regions of the world, there will continue to be a global cost associated with COVID-19 and its prolonged negative impact on certain economic sectors. Even if only the lowest-income countries were denied equal access to a vaccine and all other countries managed to immunize their populations against the virus, it could still cost the global economy $153 billion a year in GDP terms. The US would lose $16 billion a year, the EU $40 billion a year, the UK $5 billion a year, China $14 billion a year, and other high-income countries collectively $39 billion a year.
- September 28, 2020 at 09:08pm
More accurate than a rapid antigen test and almost as quick, India's CRISPR â€˜Feluda' COVID-19 test that changes colour on detection of the SARS-CoV-2 virus could be a cheaper, faster and simpler alternative to an RT-PCR diagnosis, say scientists. Named after Satyajit Ray's famed detective, the Feluda test, which is priced at Rs 500 and can deliver a result in 45 minutes, is able to differentiate SARS-CoV-2 from other coronaviruses even if genetic variations between them are minute.
- September 22, 2020 at 06:18am
- # Health Care
The Central government has made it mandatory for all students pursuing MD or MS to undergo compulsory posting at a district hospital for three months, starting from the 2020-21 academic session. A gazette notification issued last week noted that â€œall postgraduate students pursuing MD/MS in broad specialities in all medical colleges/institutions under the Indian Medical Council Act, 1956 shall undergo a compulsory residential rotation of three months in District Hospitals/District Health System as a part of the course curriculum.â€
- September 11, 2020 at 11:16pm
- Health Crisis
But the biggest crisis is Indiaâ€™s longstanding battle with tuberculosis. The country has as many as 2.7 million TB patients currently, by far the most in the world, and the disease kills an estimated 421,000 Indians each year. The current gap in care could lead to an additional 6.3 million cases and 1.4 million deaths from tuberculosis by 2025, according to a study by Zarir Udwadia, a pulmonologist at Mumbaiâ€™s P.D. Hinduja Hospital and Medical Research Centre.
The State heath department will soon open Single doctor mini clinics across tamil Nadu to treat patients for ailments other than Covi-19 . Aprt from doctor the hyper wellness clinics will have a nurse and a health assistant . The Facility expected to server 10,000 people in rural and 50,000 in urban areas.